Wide Ranks

LPTX

Leap Therapeutics, Inc.

2.92

Top Statistics
Market Cap 111 M Forward PE -2.31 Revenue Growth 0.00 %
Current Ratio 5.10 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.5040 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 78 M Total Cash Per Share 2.05 Total Debt 482000
Total Debt To Equity 0.7330 Current Ratio 5.10 Book Value Per Share 2.35
All Measures
Short Ratio 268.00 % Message Board Id finmb_118044172 Shares Short Prior Month 899103
Return On Equity -0.8054 City Cambridge Uuid 9c2a03e8-27dc-34be-8377-0c5e52ed941b
Previous Close 2.65 First Trade Date Epoch Utc 1 B Book Value 2.35
Beta 0.2170 Total Debt 482000 Volume 379385
Price To Book 1.24 Last Split Date 1 B Fifty Two Week Low 1.68
Total Cash Per Share 2.05 Shares Short Previous Month Date 1 B Target Median Price 12.00
Max Age 86400 Recommendation Mean 1.75 Sand P52 Week Change 0.3133
Target Mean Price 11.38 Net Income To Common -60343000 Short Percent Of Float 0.0313
Implied Shares Outstanding 39 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 309940 Average Volume10days 309940 Total Cash 78 M
Next Fiscal Year End 1 B Held Percent Insiders 0.1729 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 2.65
Target Low Price 5.50 Gmt Off Set Milliseconds -18000000 Fifty Day Average 2.91
Open 2.71 Free Cashflow -30067500 State MA
Dividend Yield 0.00 % Return On Assets -0.4562 Time Zone Short Name EST
Trailing Eps -1.64 Day Low 2.59 Address1 47 Thorndike Street
Shares Outstanding 38 M Price Hint 4 Target High Price 16.00
Website https://www.leaptx.com 52 Week Change 0.2978 Average Volume 274712
Forward Eps -1.25 Recommendation Key buy Compensation As Of Epoch Date 1 B
Quick Ratio 507.90 % Last Split Factor 1:10 Regular Market Day High 3.06
Is_sp_500 False Profit Margins 0.00 % Debt To Equity 0.7330
Fifty Two Week High 5.00 Day High 3.06 Shares Short 1 M
Regular Market Open 2.71 Industry Key biotechnology Earnings Growth 0.00 %
Revenue Growth 0.00 % Shares Percent Shares Out 0.0264 Operating Cashflow -50055000
Currency USD Time Zone Full Name America/New_York Market Cap 111 M
Is_nasdaq_100 False Zip 02141 Quote Type EQUITY
Industry Biotechnology Long Name Leap Therapeutics, Inc. Regular Market Day Low 2.59
Held Percent Institutions 0.4030 Current Price 2.92 Address2 Suite B1-1
Enterprise To Ebitda -0.5040 Financial Currency USD Current Ratio 5.10
Industry Disp Biotechnology Number Of Analyst Opinions 4 Country United States
Float Shares 26 M Two Hundred Day Average 2.65 Enterprise Value 32 M
Forward PE -2.31 Regular Market Volume 379385 Ebitda -64688000
Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer.

Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.

2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.

Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd.

to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand.

The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015.

Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.